The effect of GLP-1 receptor agonists in pre-clinical rodent models of Parkinson's disease: A systematic review and
GLP-1 receptor agonist
Parkinson’s Disease
Type 2 Diabetes Mellitus
Journal
Clinical parkinsonism & related disorders
ISSN: 2590-1125
Titre abrégé: Clin Park Relat Disord
Pays: England
ID NLM: 101761473
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
07
2021
revised:
16
12
2021
accepted:
16
01
2022
entrez:
7
2
2022
pubmed:
8
2
2022
medline:
8
2
2022
Statut:
epublish
Résumé
Parkinson's Disease (PD) is a progressive neurodegenerative condition associated with significant morbidity. Currently, there are limited pharmacological options and none of the therapies available are disease-modifying. This systematic review and A literature search was conducted to locate relevant pre-clinical studies. Two separate outcomes were considered. The primary outcome was indicators of dopaminergic neurotransmission. The secondary outcome was indicators of motor symptoms. Untreated PD models were compared to PD-models treated with GLP-1 receptor agonists. The final Eleven studies fit the inclusion criteria and were included in the final analysis. For the primary outcome (n = 128), there was a statistically significant relative improvement of dopaminergic neurotransmission (SMD 1.71, 95% CI = 0.74-2.68, p = 0.0005, I GLP-1 receptor agonist therapy is neuroprotective in pre-clinical models of PD. This study provides the clinical foundation and research support for the design of rigorous clinical trials to further investigate these results in human PD populations.
Sections du résumé
BACKGROUND
BACKGROUND
Parkinson's Disease (PD) is a progressive neurodegenerative condition associated with significant morbidity. Currently, there are limited pharmacological options and none of the therapies available are disease-modifying. This systematic review and
METHODS
METHODS
A literature search was conducted to locate relevant pre-clinical studies. Two separate outcomes were considered. The primary outcome was indicators of dopaminergic neurotransmission. The secondary outcome was indicators of motor symptoms. Untreated PD models were compared to PD-models treated with GLP-1 receptor agonists. The final
RESULTS
RESULTS
Eleven studies fit the inclusion criteria and were included in the final analysis. For the primary outcome (n = 128), there was a statistically significant relative improvement of dopaminergic neurotransmission (SMD 1.71, 95% CI = 0.74-2.68, p = 0.0005, I
CONCLUSIONS
CONCLUSIONS
GLP-1 receptor agonist therapy is neuroprotective in pre-clinical models of PD. This study provides the clinical foundation and research support for the design of rigorous clinical trials to further investigate these results in human PD populations.
Identifiants
pubmed: 35128376
doi: 10.1016/j.prdoa.2022.100133
pii: S2590-1125(22)00004-4
pmc: PMC8804263
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100133Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022 The Authors.
Références
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Neurochem Int. 2019 Dec;131:104583
pubmed: 31654678
Diabetes Care. 2011 Dec;34(12):2614-23
pubmed: 22110170
Neuropsychopharmacology. 2012 Jan;37(1):213-46
pubmed: 21956442
Parkinsons Dis. 2010 Dec 20;2011:658083
pubmed: 21209719
ILAR J. 2014;55(3):418-26
pubmed: 25541544
Brain Res. 2016 Sep 1;1646:354-365
pubmed: 27233809
Am J Med Sci. 2017 Sep;354(3):319-324
pubmed: 28918840
Medicine (Baltimore). 2016 May;95(18):e3549
pubmed: 27149468
Neurotox Res. 2019 Apr;35(3):635-653
pubmed: 30673988
Neuropeptides. 2018 Oct;71:70-80
pubmed: 30017231
Inflammopharmacology. 2017 Jun;25(3):369-382
pubmed: 28258522
J Parkinsons Dis. 2014;4(3):337-44
pubmed: 24662192
J Parkinsons Dis. 2019;9(1):157-171
pubmed: 30741689
BMC Med Res Methodol. 2014 Mar 26;14:43
pubmed: 24667063
Lancet. 2017 Oct 7;390(10103):1664-1675
pubmed: 28781108
Int J Neurosci. 2019 May;129(5):481-491
pubmed: 30422728
Eur J Pharmacol. 2017 Oct 5;812:82-90
pubmed: 28666800
Neuroscience. 2015 Sep 10;303:42-50
pubmed: 26141845
J Clin Invest. 2013 Jun;123(6):2730-6
pubmed: 23728174
Neuropharmacology. 2018 May 1;133:385-394
pubmed: 29462693
J Neuroinflammation. 2008 May 21;5:19
pubmed: 18492290
BMJ. 2011 Jul 22;343:d4002
pubmed: 21784880